Skip to content
CompoundSci
All peptides
Research vial labelled GHK-Cu, a Skin and cosmetic peptide studied in preclinical and clinical literature

GHK-Cu

Copper tripeptide-1

The strongest cosmetic-peptide evidence base in this library, built on controlled topical dermatology studies of skin firmness, wrinkle depth and wound repair.

The topical dermatology literature is the strongest part of this file.

General profile

Class
Skin and cosmetic
Evidence
Strong human evidence
Studied dose range
1–2 mg systemic; 0.1–2% topical in trials
Frequency in protocols
Daily
Route
Topical or subcutaneous
Half life
~4 hours
Reconstitution
2 mL bacteriostatic water per 50 mg vial
Storage
Refrigerated, light-protected, ~45 days

Timing and cycling in the literature

Usually dosed in the evening window

Daily

Most of the human evidence is topical and applied at night alongside skin repair cycles. Copper complexes also stain and should never share a syringe with anything else.

Reported cycle: 8 weeks on, 4 weeks off

Skin remodelling in the topical trials is measured over eight to twelve weeks because collagen turnover is slow.

Watch for: Metallic taste, nausea, and staining at the site. Never draw copper peptides into a syringe that has held anything else.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

  • Hard stopBody level hard stop

    GHK-Cu + Active cancer, pregnancy or heavy immunosuppression

    Absolute stop with an active cancer history

    Angiogenesis is the whole mechanism people are chasing here, and it acts everywhere in the body, not only in the tendon you care about. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference.

  • Hard stopTiming

    GHK-Cu + GLOW (GHK-Cu + BPC-157 + TB-500)

    Duplicate copper exposure

    GLOW is built around GHK-Cu. Adding standalone GHK-Cu on top pushes copper intake past anything described and copper is cumulative.

  • Separate syringesSame day fine, same syringe not

    GHK-Cu + Glutathione

    Never in one barrel

    Glutathione chelates and reduces copper, so it can strip the copper that makes GHK-Cu work at all. Same day is fine. Same syringe destroys the point of the dose.

  • Pick oneRedundant, pick one

    GHK-Cu + GLOW (GHK-Cu + BPC-157 + TB-500)

    Same target hit twice

    GLOW already carries the GHK-Cu portion.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how GHK-Cu fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: Multiple small randomised topical trials over 8 to 12 weeks.

Open questions: Injected and systemic use is not what was studied. Copper is cumulative, which matters over long runs.

Published papers

Indexed from Europe PMC and refreshed weekly. Each link opens the paper itself.

Search the full literature